{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023503","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.099699+00:00","generated_at":"2026-06-22T01:45:32.600481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"TScan Therapeutics reports Q3 net loss of $16.2M and cash of $137.3M","bullets":["Net loss $16.2M vs $15.8M YoY; revenue $3.4M vs $2.4M YoY.","Cash and equivalents $137.3M; closed $60M debt facility with K2 HealthVentures, initial $30M drawn.","Phase 1 umbrella trial for TSC-100/101 enrolling; pre-IND meeting with FDA completed for solid tumors.","Plan IND submissions for MAGE-A1 TCRs by end 2022; HPV and PRAME INDs by H1 2023.","Virtual investor event Nov 14, 2022 to detail solid tumor clinical development plans."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023503","json":"https://secwatch.observer/filing/0000950170-22-023503.json","markdown":"https://secwatch.observer/filing/0000950170-22-023503.md","text":"https://secwatch.observer/filing/0000950170-22-023503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/0000950170-22-023503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/tcrx-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:45:32.600481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61d96f104f19b7d6b1c5846c2938121f01003059","claim":"TScan Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $3.4 million.","evidence_excerpt":"be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2024. Revenue for the third quarter ended September 30, 2022, was $3.4 million, compared to $2.4 million for the third quarter ended September 30, 2021 (2021 Quarter). This increase is due to research activities related to TScan’s collaboration agreement","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/0000950170-22-023503-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}